biotech · Recurrent Pericarditis · Acute Myocarditis · CRDL
Cardiol Therapeutics
Cardiol Therapeutics clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA
- Founded
- 2017
- Employees
- 27
- Programs
- 11
- Drugs
- 31
- Patents
- 15
Cardiol Therapeutics projects
11 ClinicalTrials.gov programs sponsored by Cardiol Therapeutics.
Cardiol Therapeutics has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
100-006
Cardiol Therapeutics
Recurrent Pericarditis
1 trial -
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
CARDIOL 100-03
Cardiol Therapeutics
COVID-19
1 trial -
CCM 1862
Cardiol Therapeutics
congestive heart failure
1 trial -
CardiolRx
Cardiol Therapeutics
Recurrent Pericarditis
2 trials -
CardiolRx
Cardiol Therapeutics
Acute Myocarditis
1 trial -
CardiolRx
Cardiol Therapeutics
Acute Myocarditis
1 trial -
SEARCH
Cardiol Therapeutics
Arrhythmogenic Cardiomyopathy (ACM)
1 trial -
Impact of CardiolRxTM on Recurrent Pericarditis: An open label Pilot Study
Cardiol Therapeutics
Recurrent Pericarditis
1 trial -
ACETYLSALICYLIC ACID, PRASUGREL
Cardiol Therapeutics
St-Elevated Myocardial Infartion
1 trial -
BA-SCAD
Cardiol Therapeutics
Spontaneous Coronary Artery Dissection.
1 trial
Frequently asked questions
How many clinical projects does Cardiol Therapeutics have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.